Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Inherited cardiac diseases are often caused by a single autosomal-dominant mutation in a gene encoding for a cardiac ion channel or a sarcomere protein. These single mutations can cause life-threatening arrhythmias and sudden death in heterozygous mutation carriers. This recognition has been the basis for world-wide staggering numbers of subjects and families counselled for inherited cardiac diseases and treated based on finding disease-causing mutations. However, treating patients is greatly hampered by the growing awareness that simple carriership of a mutation often fails to predict clinical outcome: many carriers never develop clinically relevant disease while others are severely affected at a young age. It is still largely elusive what determines this large variability in disease severity, where even family members that carry an identical mutation still have large differences in disease severity. Consequently, it remains difficult to identify individuals at the highest risk, which hampers critical decisions on most appropriate therapy.
We hypothesized that single nucleotide polymorphisms (SNPs) in the 3’untranslated region (3’UTR) can drive the increased or decreased translation of one allele over the other. This is of clinical relevance when one of the two alleles harbors a disease-causing mutation. Changing the relative expression of the normal allele versus the mutation-containing allele alters the balance between normal and mutant proteins. SNPs in the 3'UTR may alter this balance as they are frequent and often heterozygous. MicroRNAs bind the 3’UTR to inhibit translation of the messenger-RNA to protein. 3’UTR SNPs can alter microRNA binding and thereby alter inhibition of the allele on which they reside.
In the attached research article, we showed the first evidence for this mechanism in long QT syndrome: SNPs in the 3’UTR of the KCNQ1 gene repress translation by creating binding sites for a cardiac microRNA. These suppressive SNPs largely determined the severity of the long QT syndrome in carriers of a KCNQ1 mutation. When the suppressive SNPs reside on the normal KCNQ1 allele, the normal allele is repressed and there is clear clinical manifestation of the mutation. However, when the suppressive SNPs reside on the mutant KCNQ1 allele, this mutant allele is repressed and there are hardly clinical manifestations of the mutation.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903Sophia Antipolis, FR
© 2017 European Society of Cardiology. All rights reserved